
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Researchers in Canada report progress in crafting a vaccine containing 10 different proteins that could prevent hepatitis C infectionless likely to adhere to their anti-HIV drug regimens than those only infected with HIV, according to a study in the February 14 edition of the journal AIDS. Canadian researchers, studying 1,186 HIVers found that HCV coinfection was a risk factor for adherence failure, defined as taking less than 95% of anti-HIV medications as prescribed. Male HIVers also were less likely to be adherent. An increase in ribavirin dosage may help improve responses to hepatitis C treatment in HIV-HCV coinfected adults, according to studies presented at the Second International Workshop on HIV and Hepatitis C Coinfection. Adjusting the dosage of ribavirin'marketed as Copegus, Rebetol, and Virazole'based on a patient's weight is more effective in controlling HCV than standard 800-milligram-per-day dosing, according to French researchers. Fatigue is commonly misdiagnosed as depression among HIV-HCV coinfected patients receiving anti-hepatitis drugs, according to a study by New York researchers. Depression is a common psychological side effect of hepatitis C therapy and a major reason treatment is halted. But the scientists reported at the Second International Workshop on HIV and Hepatitis C Coinfection that fatigue, usually caused by anemia, is more than twice as prevalent during HCV treatment than depression, but is commonly misdiagnosed. Measuring levels of ALT, an enzyme that is a marker of liver function, may be an inaccurate gauge of liver disease in HIV-HCV coinfected adults, according to a study in the January 1 edition of the Journal of Acquired Immune Deficiency Syndromes. Researchers found that 25% of patients with normal ALT levels actually had such severe liver damage that they required hepatitis treatment, with 13% having developed cirrhosis-related liver scarring. A study of 50 Spanish HIV patients who've undergone liver transplants due to hepatitis coinfection shows that the procedure is safe and effective in the short- and mid-term. The study showed that survival rates were 85% after one year, 75% after two years, and 66% after three years, levels similar to those seen in HIV-negative hepatitis patients who received liver transplants. Long-term success of hepatitis C therapy among HIV-HCV coinfected adults can be predicted by the early response to anti-hepatitis drugs after just four weeks of treatment, according to a study presented at the 13th Conference on Retroviruses and Opportunistic Infections. Among study patients who achieved a rapid virologic response to the medications, 95% maintained viral suppression through 24 weeks of treatment and 90% maintained suppression for at least another 24 weeks after drug therapy was stopped. Among those with a slower response to the drugs, only 69% achieved viral control by the end of the 24-week treatment period and only 37% maintained virologic suppression through the 24-week post-treatment follow-up.
From our Sponsors
Most Popular
Plus: Featured Video